JAMES FENLEY: Open Payments
NPI 1124667332 · TUSCALOOSA, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,616 in 159 payments from 16 companies in 2025. Trend: 2023 $2,443 · 2024 $3,002 · 2025 $2,616
Food & beverage: $2,426Education: $190
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 24 | $356 |
| Janssen Biotech, Inc. | 13 | $326 |
| ABBVIE INC. | 31 | $305 |
| UCB, Inc. | 9 | $260 |
| GENZYME CORPORATION | 8 | $234 |
| PFIZER INC. | 17 | $175 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 3 | $170 |
| Regeneron Healthcare Solutions, Inc. | 7 | $170 |
| Arcutis Biotherapeutics, Inc. | 7 | $151 |
| Galderma Laboratories, L.P. | 24 | $144 |
Products named: DUPIXENT, TREMFYA, Bimzelx, COSENTYX, RINVOQ, CIBINQO, Zoryve, NEMLUVIO.
Industry payments across AL — which companies pay providers there.
